Lung Cancer Therapy Annual 7

Highly Commended, BMA Medical Book Awards 2013

Oncology research and practice in lung cancer continues to develop rapidly. This latest edition of an acclaimed reference briefs the oncology community with a review of the recent literature, emphasizing the most significant therapeutic advances. The expert contributions of Lung Cancer Therapy Annual 7 offer an update of the impact that this information will have on the day-to-day management of the lung cancer patient.

New to the seventh edition are four new chapters on the treatment of non-small cell lung cancer (NSCLC) and a new chapter on thymoma. Additional topics include:

• Oncogenic driver mutations
• First line therapy of advanced non-small cell lung cancer without activating EGFR mutation
• Second line therapy of non-small cell lung cancer
• Adjunct and neoadjunct therapy of non-small cell lung cancer
• Advances in surgery of lung cancer; advances in radiotherapy of lung cancer
• Mesothelioma
• Thymic tumors

Rolf A. Stahel, M.D. is head of the Center for Lung and Thoracic Oncology and Senior Staff Physician at the Clinic of Oncology, University Hospital of Zürich as well as Titular Professor of Medicine at the University of Zürich, Switzerland. He is certified in Internal Medicine and Medical Oncology by both the American and Swiss Board. His major interest is thoracic oncology, including multidisciplinary treatment approaches, translational research, and targeted therapy.